BIA Separations
BIA Separations, a Sartorius company, develops and manufactures monolithic chromatography columns (CIMmultus) for downstream purification of AAV vectors, proteins, and viral vectors, serving gene therapy and biopharmaceutical manufacturers globally through direct enterprise sales.
- Company typePrivate
- Founded1998
- HeadquartersAjdovscina, Slovenia
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What BIA Separations does
BIA Separations is a Slovenia-based developer and manufacturer of monolithic chromatography technology used in downstream purification of complex biological products. Founded in 1998 and headquartered in Ajdovščina with a second facility in Bled, the company operates under the Sartorius BIA Separations brand as part of the Sartorius Group, and employs 101–250 people. Its core product line is the CIMmultus family of Convective Interaction Media (CIM) monolithic chromatography columns, with CIMmultus QA HR positioned for scalable AAV capsid enrichment in gene therapy manufacturing, delivering documented performance of 88% ± 9% full capsid purity and 77% ± 3% genome recovery across scales from 1 mL to 8000 mL.
The company's technology is built on a proprietary monolithic stationary phase architecture that supports both bind-elute and flow-through operating modes, with an optimized step elution method that reduces process time relative to traditional linear-gradient approaches. Revenue is generated through direct enterprise sales of chromatography columns and consumables to gene therapy manufacturers (primary segment) and broader biopharmaceutical manufacturers producing proteins, vaccines, and viral vectors (secondary segment). Distribution is direct and global, leveraging Sartorius' bioprocessing sales infrastructure.
Complementing its product business, BIA Separations invests in scientific community-building activities, most notably the MSS (Monolith Summer School / bioprocessing symposium) series — with MSS2026 scheduled as a three-day event in Bled, Slovenia on September 14–16, 2026, combined with wet lab workshops at the Ajdovščina facility — functioning as both a customer-engagement and thought-leadership mechanism targeting the AAV/gene therapy and biologics manufacturing communities.
BIA Separations firmographics
Firmographics- Name
- BIA Separations
- Legal name
- BIA Separations
- Website
- https://biaseparations.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- BIA Separations, a Sartorius company, develops and manufactures monolithic chromatography columns (CIMmultus) for downstream purification of AAV vectors, proteins, and viral vectors, serving gene therapy and biopharmaceutical manufacturers globally through direct enterprise sales.
- Ownership category
- akta.pro rank
BIA Separations industry classification
Industry- Product category
- Bioprocessing Chromatography Consumables
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Downstream Processing & Purification Technologies (chromatography, filtration, centrifugation) (HLAAAJAB)
- akta.pro secondary industries
- Bioprocess Consumables & Reagents (resins, membranes, media components, buffers) (HLAAAJAI), Analytical Instruments & Chromatography Systems (HLAGAIAA)
Keywords
Where BIA Separations is headquartered
LocationHeadquarters
- HQ city
- Ajdovscina
- HQ country
- Slovenia
- HQ region
- Europe
Offices2 records
Markets served
BIA Separations business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales
Revenue model
- Chromatography Products and Consumables: Sale of CIMmultus monolithic chromatography columns and related consumables for biopharmaceutical purification applications
Go-to-market motion2 records
Distribution channels1 record
Marketing channels1 record
BIA Separations product offering
Product offeringCore offering
BIA Separations develops, manufactures, and supplies CIMmultus monolithic chromatography columns, with the CIMmultus QA HR (high-resolution) line as a flagship product, for downstream purification of biological products including AAV vectors, viral vectors, and proteins. The columns are used by gene therapy manufacturers and biopharmaceutical manufacturers to capture, purify, and polish large biomolecules in industrial and clinical-scale bioprocessing workflows.
Product overview
BIA Separations, a Sartorius company, provides monolithic chromatography products for biopharmaceutical purification. The core product offering includes the CIMmultus QA HR line of monolithic chromatography columns designed for scalable AAV vector manufacturing and gene therapy production. The company also offers bioprocessing symposiums (MSS) and wet lab workshops as part of their customer engagement and training services.
Differentiator
Problem solved
Functional benefit
Brands
- CIMmultus: Monolithic chromatography columns for biopharmaceutical purification including AAV vectors, proteins, and viral vectors.
Quantifiable outcome
- 88% ± 9% full capsid purity achieved across scales from 1 mL to 8000 mL
- +2 more outcomes
Companies that use BIA Separations
Customer profileSegments2 records
Ideal customer profiles2 records
BIA Separations technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
BIA Separations partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Sartorius (as part of Sartorius BIA Separations)coreBIA Separations operates under the Sartorius brand as Sartorius BIA Separations, indicating a subsidiary or integrated business unit relationship within the larger Sartorius Group, a global life science and bioprocessing company.
Scale indicators1 record
Recent moves4 records
Expansion highlights4 records
BIA Separations competitors and assessment
Company assessmentEmerging players
- Avantor: Supplies bioprocessing consumables including chromatography resins, buffers, and single-use solutions to gene therapy and biologics manufacturers, with increasing focus on the viral vector purification workflow.
- Asahi Kasei Medical (Planova): Provides virus filtration and select purification technologies used in biopharmaceutical manufacturing, overlapping with BIA's downstream processing solutions for viral vectors and biologics.
Broad incumbents
- Sartorius AG: Parent/affiliated bioprocessing platform offering a broad portfolio of filtration, fermentation, and purification solutions. BIA operates within this portfolio, so Sartorius is both parent and broader incumbent competitor in adjacent bioprocessing categories.
Direct peers
- Repligen: Specializes in bioprocessing solutions including OPUS pre-packed chromatography columns and filtration products used in gene therapy and biologics manufacturing — competing directly in downstream purification consumables.
- Merck KGaA (MilliporeSigma): Provides a broad portfolio of chromatography resins, membrane adsorbers, and bioprocessing consumables for biologics and viral vector purification, directly competing in downstream processing.
- Bio-Rad Laboratories: Supplies chromatography media, NGC systems, and process-scale columns for biopharmaceutical purification, overlapping with BIA's downstream purification offering for biologics and viral vectors.
- Thermo Fisher Scientific: Through its Patheon and bioproduction units, offers POROS chromatography resins widely used for AAV and viral vector purification, positioning it as a primary alternative to BIA's monolithic columns.
- Tosoh Bioscience: Manufactures chromatography resins (TOYOPEARL and TSKgel) used in biologics purification, including applications in gene therapy and vaccine manufacturing — a direct competitor in resin-based downstream processing.
- Cytiva: Global bioprocessing leader offering ÄKTA chromatography systems and resin-based columns for downstream purification of biologics, viral vectors, and AAV — directly competing with BIA's monolithic offering in gene therapy and vaccine workflows.
- Purolite (Ecolab Life Sciences): Manufactures chromatography resins including Praesto agarose-based resins targeted at AAV and biologics purification, positioning it as a direct competitor in process-scale downstream purification.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
BIA Separations social profiles
Digital presenceBIA Separations financial estimates
Financial estimateRevenue estimate
Valuation estimate
BIA Separations leadership team
Management profileNumber of profiles
Profiles2 records
BIA Separations funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BIA Separations M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BIA Separations
What does BIA Separations do?
BIA Separations develops, manufactures, and supplies CIMmultus monolithic chromatography columns, with the CIMmultus QA HR (high-resolution) line as a flagship product, for downstream purification of biological products including AAV vectors, viral vectors, and proteins. The columns are used by gene therapy manufacturers and biopharmaceutical manufacturers to capture, purify, and polish large biomolecules in industrial and clinical-scale bioprocessing workflows.
Is BIA Separations a public or private company?
BIA Separations is a private company. It is classified as corporate owned and is currently operating.
When was BIA Separations founded?
BIA Separations was founded in 1998. It employs 101 to 250 people.
Where is BIA Separations based?
BIA Separations is headquartered in Ajdovscina, Slovenia, in the Europe region.
How does BIA Separations make money?
One revenue line is on record: chromatography Products and Consumables.
Who are BIA Separations's main competitors?
Emerging players on record are Avantor and Asahi Kasei Medical (Planova). Sartorius AG is listed as a broad incumbent. Direct peers are Repligen, Merck KGaA (MilliporeSigma), Bio-Rad Laboratories, Thermo Fisher Scientific, Tosoh Bioscience, Cytiva and Purolite (Ecolab Life Sciences).
Does BIA Separations have an API?
No public API is recorded for BIA Separations.
What industry is BIA Separations in?
BIA Separations's product category is Bioprocessing Chromatography Consumables. Its primary akta.pro industry code is HLAAAJAB, Downstream Processing & Purification Technologies (chromatography, filtration, centrifugation), with a secondary code of HLAAAJAI, Bioprocess Consumables & Reagents (resins, membranes, media components, buffers). Its NAICS code is 334516 and its SIC code is 3826.